Jeff L Vacirca insider trades: Caris Life Sciences (CAI) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jeff reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | CAI | ↑ Buy | 31,050 | $16.15 | $501K | Direct | May 12, 2026 (1d) |
| Jun 11, 2024 | ASRT | ↑ Buy | 10,000 | $1.11 | $11K | Direct | Jun 12, 2024 (1d) |
| Nov 30, 2022 | SPPI | ↑ Buy | 50,000 | $0.45 | $23K | Direct | Dec 2, 2022 (2d) |
| Jun 26, 2019 | ODT | ↑ Buy | 19,231 | $26.00 | $500K | Direct | Jun 28, 2019 (2d) |
| Mar 4, 2019 | ODT | ↑ Buy | 3,000 | $17.00 | $51K | Direct | Mar 7, 2019 (3d) |
| Dec 12, 2017 | ODT | ↑ Buy | 1,000 | $23.30 | $23K | Direct | Dec 14, 2017 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other CAI insiders
Open-market trades in the last 12 months
About Jeff L Vacirca's insider trades
Jeff L Vacirca is a director at Caris Life Sciences (CAI). Since Dec 12, 2017, Jeff has reported 6 open-market purchases worth $1.1M and no sales on SEC Form 4. In the last 12 months: 1 buy ($501K).
Their filings also include grants and awards (24 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CAI insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.